Needham analyst Michael Matson (NYSE:MATX) maintained a Buy rating on Steris (NYSE:STE) plc on Tuesday, setting a price target of $254, which is approximately 7.73% above the present share price of $235.78.
Matson expects Steris plc to post earnings per share (EPS) of -$0.24 for the fourth quarter of 2021.
The current consensus among 5 TipRanks analysts is for a Strong Buy rating of shares in Steris, with an average price target of $245.6.
The analysts price targets range from a high of $255 to a low of $230.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $968.42 million and a net profit of $14.34 million. The company's market cap is $23.52 billion.
According to TipRanks.com, Needham analyst Michael Matson is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 16.8% and a 64.86% success rate.
STERIS Plc (Ireland) engages in the manufacture of medical and surgical equipment. The company was founded on December 22, 2016 and is headquartered in Dublin, Ireland.